Doceree Inc., a U.S.-headquartered company specializing in physician-only programmatic marketing platforms, has officially unveiled RepTwin, an artificial intelligence–powered ad format designed to redefine how pharmaceutical companies and healthcare professionals (HCPs) interact. Announced during Fierce Pharma Week 2025 in Philadelphia, the launch introduces what Doceree calls the industry’s first Conversation Layer, enabling virtual brand representatives to be available to physicians 24/7 within their existing digital workflows.
At its core, RepTwin aims to address a longstanding challenge in the pharmaceutical industry: the steady decline of face-to-face access between sales representatives and healthcare providers. According to data shared at the event, approximately 65 percent of physicians in the United States now limit or restrict rep access, while those who do meet with brand representatives typically allow only a few minutes of interaction. RepTwin’s artificial intelligence model is designed to fill this engagement gap by providing compliant, real-time, brand-trained support across multiple digital environments, including electronic health record (EHR) platforms, specialist medical publications, brand websites, and clinical training platforms.
Why is Doceree’s RepTwin launch significant for pharmaceutical companies and healthcare marketing?
The introduction of Doceree’s RepTwin comes at a pivotal moment for the global life sciences industry. Over the past decade, pharmaceutical manufacturers have struggled with limited access to clinicians due to stricter compliance regulations, time constraints in busy practices, and growing reliance on digital tools for medical decision-making. The COVID-19 pandemic accelerated a broader digital transformation, reducing in-person interactions while normalizing telehealth consultations and remote detailing.
Historically, pharmaceutical sales representatives were a critical channel for disseminating product knowledge, clinical trial data, and brand messages directly to prescribing physicians. At its peak in the early 2000s, the U.S. employed more than 100,000 pharma reps. But as hospitals and practices tightened access, the average in-person meeting shrank to just two or three minutes, often limited to sample drops or quick reminders. This constrained format reduced opportunities for meaningful engagement, creating challenges for brand differentiation in increasingly crowded therapeutic categories such as oncology, immunology, and cardiovascular health.
RepTwin addresses this pain point by embedding a digital surrogate for the human representative directly into the physician’s workflow. The tool allows clinicians to ask questions, review updated clinical data, and receive brand-approved information at the point of care. Unlike traditional chatbots, the RepTwin platform is built on an AI engine specifically trained on a pharmaceutical company’s own scientific data, marketing content, and compliance guidelines. It ensures that every response is HIPAA-compliant, GDPR-aligned, SOC 2 certified, and consistent with medical, legal, and regulatory (MLR) approvals from day one.
How does RepTwin’s always-available virtual rep model address shrinking access to physicians?
One of the most pressing issues facing pharmaceutical sales forces is the shrinking window of opportunity to meet healthcare providers. Surveys conducted by industry groups such as ZS Associates and the American Medical Association indicate that physicians now spend less than 2 minutes on average with reps, if they accept meetings at all. RepTwin circumvents this by offering an on-demand engagement model.
The system integrates seamlessly with more than 2,000 specialist medical publishers and over 150 EHR systems, including widely used platforms such as Epic and Cerner. This reach ensures that physicians do not need to leave their clinical workflows to access relevant brand information. Instead, RepTwin surfaces when a physician is reviewing a patient’s chart or researching treatment protocols, offering contextually relevant insights. For example, an oncologist evaluating treatment options for a patient with non-small cell lung cancer might receive a prompt from RepTwin containing the latest data from a phase III clinical trial of a targeted therapy.
This just-in-time availability could significantly improve the timeliness and utility of pharma-physician interactions, reducing friction and ensuring that doctors have the resources they need without interrupting their clinical flow. For time-pressed practitioners, this represents a substantial efficiency gain.
What are the key features that set RepTwin apart in digital healthcare engagement?
Doceree has positioned RepTwin as more than just another digital detailer or medical chatbot. The solution is defined by several differentiating features that align with both physician needs and regulatory demands.
The first is constant availability. Unlike traditional sales reps constrained by office hours and appointment windows, the virtual rep is accessible around the clock. This means that whether a physician is reviewing cases late at night or preparing for patient consultations early in the morning, they can instantly connect with RepTwin for information.
Secondly, the platform is specifically trained on brand content, including clinical trial data, scientific publications, product guidelines, and competitive intelligence. This ensures that interactions are not generic but instead tailored to the therapeutic context and aligned with the pharmaceutical company’s voice. Importantly, every interaction is compliant from the outset, with built-in adherence to HIPAA, GDPR, and other privacy regulations. This feature addresses one of the industry’s most significant pain points: the risk of non-compliant communication in digital engagement.
Another distinguishing aspect is multi-modal interaction. RepTwin supports video, voice, and text communication, giving physicians the flexibility to choose the format that best fits their clinical environment. This is particularly relevant as healthcare systems increasingly rely on digital platforms to support telemedicine and remote care delivery. By meeting HCPs where they already spend their time—within EHRs, online medical references, and brand platforms—RepTwin enhances the likelihood of meaningful engagement.
How does the RepTwin launch fit into the evolution of digital engagement in life sciences?
The pharmaceutical industry has been gradually shifting toward digital engagement models for over a decade. The decline of traditional sales reps has been accompanied by the rise of multichannel marketing strategies, which use a combination of email, webinars, virtual events, and digital advertising to reach physicians. However, many of these approaches lack the personalization and interactivity that HCPs value.
RepTwin seeks to fill that gap by offering what Doceree describes as a “human-like” engagement model that is simultaneously scalable. The platform leverages artificial intelligence to simulate real-time conversations while drawing on continuously updated brand content. This approach aims to strike a balance between personalization and compliance, two critical elements for building trust in physician–industry interactions.
The solution also aligns with the broader industry movement toward value-based care and evidence-driven decision-making. By ensuring that physicians receive accurate, up-to-date clinical information at the point of care, RepTwin could help support better treatment outcomes. This is particularly important as pharmaceutical companies face pressure to demonstrate not just efficacy but also real-world value in terms of patient outcomes and healthcare cost savings.
What challenges could Doceree face in scaling RepTwin across different healthcare markets worldwide?
While RepTwin’s value proposition is clear, the road to widespread adoption will not be without obstacles. Regulatory diversity across global healthcare markets poses a significant challenge. For instance, while compliance frameworks like GDPR apply across the European Union, individual countries have varying rules governing pharmaceutical promotion and physician engagement. Similarly, in the United States, the Food and Drug Administration (FDA) closely scrutinizes how drug manufacturers communicate with healthcare providers, particularly regarding promotional claims. Doceree will need to ensure that RepTwin remains adaptable to different regulatory environments without compromising its real-time responsiveness.
There are also broader concerns about physician trust in AI-powered communication tools. While some clinicians welcome the convenience, others may remain skeptical about the reliability of AI-generated responses or worry about potential biases in the data used to train such systems. To succeed, Doceree must emphasize transparency, continuous data validation, and robust governance processes.
On the commercial side, pharmaceutical companies may hesitate to shift significant portions of their marketing budgets toward unproven technologies, particularly at a time when many firms are under pressure to demonstrate cost containment. Adoption may begin with pilot projects focused on specific therapeutic areas or regions, with broader implementation contingent on measurable outcomes.
The unveiling of RepTwin at Fierce Pharma Week 2025 positions Doceree at the forefront of AI-driven healthcare marketing transformation. By offering a 24/7 virtual representative that is both brand-trained and compliant, the company is attempting to solve one of the pharmaceutical industry’s most pressing engagement challenges. While questions remain about scalability, regulatory harmonization, and physician trust, the early momentum suggests that digital surrogates for sales reps could become a defining feature of the next phase of pharma–HCP interaction. For investors, marketers, and clinicians alike, Doceree’s move highlights the growing role of artificial intelligence in shaping the future of pharmaceutical communications and the broader healthcare ecosystem.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
